| Website | amakem.com |
| Category | BioTech |
| Phone | 32-(0)-11-286-982 |
| info@amakem.com | |
| Employees |
| TOTAL | $25.4M |
| FUNDING TOTAL | $25.4M |
| Series A, 9/11 Forbion Capital Partners Credit Agricole Private Equity Vesalius Biocapital Partners LRM | €18M |
Amakem is a kinase platform company focusing on ophthalmology and is developing new treatments for serious eye conditions. Amakem’s product pipeline is based on its unique ‘Localized Drug Action’ platform which is designed to generate safe and effective novel kinase inhibitors that minimize systemic exposure with the aim of reducing side effects.
